x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012844
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Monkey |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human SMG-1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SMG1 |
| UniProt No. | Q96Q15 |
| Gene ID | 23049 |
| Gene Description | SMG-1 is a member of the phosphoinositide 3-kinase-related kinase family, which includes ATM, ATR, mTOR, DNA-PKcs, and TRRAP. Activated by DNA damage, SMG-1 has been shown to phosphorylate p53 and hUpf1. hUpf1 is a subunit of the surveillance complex that allows degradation of messenger RNA species containing premature termination codons. This process, known as nonsense-mediated mRNA decay, prevents the translation of truncated forms of proteins that may result in gain of function or dominant negative species. NMD occurs under normal cellular conditions as well as in response to damage. SMG-1 has also been shown to affect cell death receptor signaling and to protect cells from extrinsically induced apoptotic cell death. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
